ABDA-KBV-Modell / ARMIN
The ABDA-KBV model is a jointly developed concept of the Federal Association of German Pharmacists' Associations (ABDA) and the National Association of Statutory Health Insurance Physicians (KBV) to improve the supply of pharmaceuticals to the population in Germany. The model is to be built on three pillars: drug prescription, medication catalog and medication management. The model project is anchored in Section 64a of Book Five of the Social Security Code .
Three pillars of the ABDA-KBV model
Active ingredient regulation
The doctor no longer prescribes the finished drug from a specific company, but rather an active ingredient with the exact strength and quantity. The pharmacist then chooses a discounted finished drug himself . The recourse rule for the physician falls away thereby. In addition, the pharmaceutical companies should emphasize the name of the active ingredient on the packaging of the drug. The experts hope that this will minimize the risk of confusion, especially for multimorbid patients .
Medication catalog
In 2014, a list of medicinal products recommended for all indications and economical for statutory health insurance was drawn up. This list is intended to save money. In justified individual cases, the doctor can deviate from the medication catalog, i.e. also prescribe other active ingredients. The medication catalog is not a positive list for drugs .
Medication management
The last pillar is the most interesting point - the joint medication management between doctors and pharmacists. A medication plan should be drawn up, especially for multimorbid patients with polymedication - i.e. patients who have to take more than five systemically acting drugs on a long-term basis. The experts expect the additional pharmaceutical care to improve adherence to therapy and reduce drug-related problems. In the long term, they hope that the higher therapy safety will result in fewer hospital stays, a better quality of life for the patients and, above all, cost savings for the statutory health insurance.
Total savings and rewards
According to forecasts by the ABDA and KBV, the cost savings are around 2.1 billion euros. In view of these figures, doctors and pharmacists are to be rewarded in equal parts with 320 euros each per patient and a total of 700 million euros per year.
News and outlook
The Supply Structure Act, which came into force in early 2012, expressly allows the ABDA-KBV model to be tested in a test region. This provides the legal prerequisites for putting the model into practice for the first time. The minimum duration of the trial phase is three years.
The Saxon and Thuringian State Pharmacists Association, the Association of Statutory Health Insurance Physicians of the two states and the health insurance company AOK PLUS have decided to implement this concept and signed a "contract for a model project according to Section 63 SGB V to optimize the supply of pharmaceuticals in Saxony and Thuringia (ARMIN)" closed. This came into force on April 1, 2014 and is being implemented in stages.
literature
- Ulrich Jaehde, Roland Radziwill, Stefan Mühlebach, Walter Schunack: Textbook of clinical pharmacy . 2nd Edition. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart 2003. ISBN 3-8047-1939-2
credentials
- ↑ Supply of pharmaceuticals to the population in Germany on akwl.de
- ↑ Positive list for drugs on Aerzteblatt.de